Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
4(50%)
Results Posted
50%(1 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
5
63%
Ph phase_2
3
38%

Phase Distribution

5

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
5(62.5%)
Phase 2Efficacy & side effects
3(37.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

4

trials recruiting

Total Trials

8

all time

Status Distribution
Active(4)
Completed(2)
Terminated(2)

Detailed Status

Recruiting2
Terminated2
Active, not recruiting2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
4
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (62.5%)
Phase 23 (37.5%)

Trials by Status

recruiting225%
terminated225%
active_not_recruiting225%
completed225%

Recent Activity

4 active trials
Showing 5 of 8
active_not_recruitingphase_1

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

NCT04930783
recruitingphase_2

Converting HR+ Breast Cancer Into an Individualized Vaccine

NCT03804944
active_not_recruitingphase_1

The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

NCT05010200
recruitingphase_1

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

NCT05029999
terminatedphase_2

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

NCT04536077
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04930783Phase 1

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Active Not Recruiting
NCT03804944Phase 2

Converting HR+ Breast Cancer Into an Individualized Vaccine

Recruiting
NCT05010200Phase 1

The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

Active Not Recruiting
NCT05029999Phase 1

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Recruiting
NCT04536077Phase 2

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Terminated
NCT03329950Phase 1

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Completed
NCT01465139Phase 1

A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers

Completed
NCT02200380Phase 2

A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs

Terminated

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8